Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q2 EPS of ($1.23), $0.13 worse than the analyst estimate of ($1.10). Revenue for the quarter came in at $1 million versus the consensus estimate of $750.11 thousand.

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.